Clinical Trial Update: A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine, cisplatin, and LY293111 in non-small cell lung cancer has completed. Sponsor: Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• LY293111

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED